• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?以破产为代价的新型抗癌药物:肿瘤学家会告知患者其在延长生命天数/周数方面的益处吗?
Oncologist. 2014 Dec;19(12):1291. doi: 10.1634/theoncologist.2014-0263.
2
Optional copayments on anti-cancer drugs.抗癌药物的选择性自付费用。
BMJ. 2013 Jan 24;346:f349. doi: 10.1136/bmj.f349.
3
A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.一种用于估算欧洲新型肿瘤药物基于价值的价格的药物经济学建模方法。
J Oncol Pharm Pract. 2012 Mar;18(1):57-67. doi: 10.1177/1078155210390724. Epub 2011 Mar 7.
4
Should the cost of care for patients with glioblastoma influence treatment decisions?胶质母细胞瘤患者的护理费用会影响治疗决策吗?
Continuum (Minneap Minn). 2012 Apr;18(2):416-20. doi: 10.1212/01.CON.0000413667.65668.ae.
5
NICE confirms advanced breast cancer drug is too expensive for NHS.英国国家卫生与临床优化研究所确认,一种晚期乳腺癌药物对英国国民医疗服务体系来说过于昂贵。
BMJ. 2014 Aug 7;349:g5078. doi: 10.1136/bmj.g5078.
6
Rewarding value creation to promote innovation in oncology: The importance of considering the global product life cycle.奖励价值创造以促进肿瘤学创新:考虑全球产品生命周期的重要性。
Oncologist. 2010;15 Suppl 1:49-57. doi: 10.1634/theoncologist.2010-S1-49.
7
Shortening the infusion time of anticancer drugs: who will benefit?
J Clin Oncol. 2007 Jul 1;25(19):2642-3. doi: 10.1200/JCO.2007.10.7334.
8
NICE says drug for metastatic breast cancer is unaffordable for NHS.英国国家卫生与临床优化研究所表示,用于治疗转移性乳腺癌的药物对英国国民医疗服务体系来说难以承受。
BMJ. 2014 Apr 22;348:g2888. doi: 10.1136/bmj.g2888.
9
Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.曲妥珠单抗(赫赛汀)治疗 HER2 过表达转移性乳腺癌的成本效益分析。
Am J Clin Oncol. 2009 Oct;32(5):492-8. doi: 10.1097/COC.0b013e3181931277.
10
Do oncologists believe new cancer drugs offer good value?肿瘤学家认为新型抗癌药物具有良好的价值吗?
Oncologist. 2006 Feb;11(2):90-5. doi: 10.1634/theoncologist.11-2-90.

引用本文的文献

1
Editorial: Multimodal management of advanced gastric cancer.社论:晚期胃癌的多模式管理
Front Oncol. 2022 Dec 29;12:1113856. doi: 10.3389/fonc.2022.1113856. eCollection 2022.
2
Redefining the Treatment Endpoints in Oncology.重新定义肿瘤学的治疗终点。
Oncologist. 2021 Mar;26(3):e521. doi: 10.1002/onco.13688. Epub 2021 Feb 12.
3
Social taboos: a formidable challenge in cancer care.社会禁忌:癌症护理面临的艰巨挑战。
BMJ Case Rep. 2021 Jan 11;14(1):e236095. doi: 10.1136/bcr-2020-236095.
4
Hyperthermic Intraperitoneal Chemotherapy - Fading Perspective in the Light of Modern Systemic Chemotherapy?热灌注腹腔化疗——鉴于现代全身化疗,其前景渐趋黯淡?
Visc Med. 2018 Dec;34(6):412-416. doi: 10.1159/000493493. Epub 2018 Oct 30.
5
ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.欧洲肿瘤内科学会国际联盟关于欧洲以外国家抗肿瘤药物的可及性、自付费用和可获得性的研究
Ann Oncol. 2017 Nov 1;28(11):2633-2647. doi: 10.1093/annonc/mdx521.

本文引用的文献

1
Quality of life in the trastuzumab for gastric cancer trial.曲妥珠单抗治疗胃癌临床试验中的生活质量。
Oncologist. 2014 Jul;19(7):712-9. doi: 10.1634/theoncologist.2014-0058. Epub 2014 Jun 20.
2
Delivery of affordable and equitable cancer care in India.在印度提供负担得起且公平的癌症护理。
Lancet Oncol. 2014 May;15(6):e223-33. doi: 10.1016/S1470-2045(14)70117-2. Epub 2014 Apr 11.
3
Cancer drugs in the United States: Justum Pretium--the just price.美国的抗癌药物:公平价格——合理的价格。
J Clin Oncol. 2013 Oct 1;31(28):3600-4. doi: 10.1200/JCO.2013.49.1845. Epub 2013 May 6.
4
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.曲妥珠单抗治疗人表皮生长因子受体 2 阳性胃或胃食管交界部转移性腺癌。
Health Technol Assess. 2011 May;15 Suppl 1:33-42. doi: 10.3310/hta15suppl1/04.
5
Insured yet vulnerable: out-of-pocket payments and India's poor.参保却脆弱:自付费用与印度的贫困人口
Health Policy Plan. 2012 May;27(3):213-21. doi: 10.1093/heapol/czr029. Epub 2011 Apr 12.
6
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.曲妥珠单抗联合化疗与单纯化疗治疗 HER2 阳性晚期胃或胃食管交界腺癌(ToGA):一项开放标签、随机对照的 3 期临床试验。
Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19.
7
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.生命价值几何:西妥昔单抗、非小细胞肺癌与那4400亿美元的问题
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
8
Medical bankruptcy in the United States, 2007: results of a national study.2007年美国的医疗破产:一项全国性研究的结果
Am J Med. 2009 Aug;122(8):741-6. doi: 10.1016/j.amjmed.2009.04.012. Epub 2009 Jun 6.

以破产为代价的新型抗癌药物:肿瘤学家会告知患者其在延长生命天数/周数方面的益处吗?

New cancer drugs at the cost of bankruptcy: will the oncologist tell the patients the benefit in terms of days/weeks added to life?

作者信息

Garg Pankaj Kumar, Jain Bhupendra Kumar

机构信息

Department of Surgery, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, Delhi, India.

出版信息

Oncologist. 2014 Dec;19(12):1291. doi: 10.1634/theoncologist.2014-0263.

DOI:10.1634/theoncologist.2014-0263
PMID:25480341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4257748/
Abstract

In addition to considerations of possible cancer treatments reducing quality of life, the cost effectiveness of such treatments must also be a factor when determining treatments. Some patients have opted for expensive new treatments, leading to high financial risk but only modest results. Oncologists must explain to patients the expected benefits of treatments in terms of absolute values to allow patients to make informed decisions.

摘要

除了考虑可能的癌症治疗会降低生活质量外,在确定治疗方案时,此类治疗的成本效益也必须是一个考量因素。一些患者选择了昂贵的新疗法,这带来了很高的经济风险,但效果却并不显著。肿瘤学家必须向患者解释治疗的预期益处的绝对值,以便患者能够做出明智的决定。